Drugs / CBA-1535
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07016997 | Jun 2022 → Dec 2025 overdue | refractory malignant neoplasm | Chiome Bioscience Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-02-16 | Chiome Bioscience Inc. | Regulatory がん治療用抗体CBA-1535の治験計画届の提出に関するお知らせ xj-storage.jp ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-10 | Chiome Bioscience Inc. | 米国癌学会（AACR）年次総会での「PCDC」、「CBA-1205」および「CBA-1535」の発表のお知らせ xj-storage.jp ↗ |
| 2022-02-16 | Chiome Bioscience Inc. | がん治療用抗体CBA-1535の治験計画届の提出に関するお知らせ xj-storage.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBA-1535 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07016997 ↗ |
| Modality | Protein / enzyme biologic | “CBA-1535, Recombinant Protein Tribody” NCT07016997 ↗ |
| Route | Intravenous | “Patients will receive CBA-1535 as weekly IV infusion” NCT07016997 ↗ |